8-K: Veru Settles Onconetix Debt, Secures Cash & Equity

Veru Inc. resolves $8.8 million defaulted promissory notes with Onconetix, receiving $6.3 million cash and equity instruments.

Summary

• Veru Inc. (the Company) entered into a Settlement Agreement and Release with Onconetix, Inc. (the Borrower) on September 22, 2025, to resolve defaulted promissory notes.
• An aggregate of $8,826,155.41 was payable to Veru Inc. under the Promissory Notes and related amendments.
• Veru Inc. agreed to accept a cash payment of $6,326,155.41, 3,125 shares of the Borrower's Series D Convertible Preferred Stock, and 846,975 warrants to purchase shares of the Borrower's common stock.
• Each share of the Series D Preferred Stock has a stated value of $1,000 per share, totaling $3,125,000 in stated value for the preferred stock component.
• The total stated value of the settlement package (cash plus preferred stock stated value) is $9,451,155.41.
• The Promissory Notes and Amended Forbearance Agreement terminated upon payment of the Settlement Amounts by Onconetix, Inc. on September 24, 2025.

Sentiment

Score: 7

Explanation: The company successfully resolved a significant defaulted debt, recovering a substantial cash portion and equity instruments whose stated value, combined with the cash, exceeds the original debt amount. This is a positive resolution, though the future value and liquidity of the preferred stock and warrants remain uncertain.

Positives

• Successfully resolved defaulted promissory notes totaling $8,826,155.41, removing a significant financial uncertainty.
• Received a substantial cash payment of $6,326,155.41.
• Acquired 3,125 shares of Series D Convertible Preferred Stock with a stated value of $1,000 per share, totaling $3,125,000, providing potential future value.
• Received 846,975 warrants to purchase common stock, offering additional potential upside.
• The total stated value of the settlement package ($9,451,155.41) exceeds the original amount due ($8,826,155.41) by $625,000.

Negatives

• The immediate cash payment of $6,326,155.41 is less than the total amount originally due of $8,826,155.41.
• There is no assurance as to whether and when Veru Inc. will be able to receive cash proceeds from the Series D Preferred Stock, the Warrants, or any common stock acquired upon exercise of the Warrants, introducing liquidity risk.

Risks

• Uncertainty regarding the future value and liquidity of the Series D Preferred Stock and Warrants received from Onconetix, Inc.
• Potential for delays or difficulties in monetizing the equity instruments into cash proceeds.

Future Outlook

There is no assurance as to whether and when Veru Inc. will be able to receive any cash proceeds from the shares of Series D Preferred Stock, the Warrants, or any shares of Onconetix, Inc.'s common stock that Veru Inc. might acquire upon exercise of the Warrants.

Management Comments

• Veru Inc., through its management, entered into the Settlement Agreement and Release to resolve outstanding debt obligations, indicating a strategic move to address and conclude prior financial arrangements.

Industry Context

NA

Stakeholder Impact

• Shareholders benefit from the resolution of a significant defaulted debt, which removes a financial overhang and provides a mix of immediate cash and potential future equity upside.
• The company's financial position is strengthened by the cash inflow and the conversion of a defaulted debt into potentially valuable assets.

Next Steps

• Veru Inc. will need to evaluate strategies for monetizing the Series D Preferred Stock and Warrants received from Onconetix, Inc. to realize their full value.

Key Dates

Recommendation

While the resolution of a defaulted debt is a positive step, providing clarity and some cash, the long-term value and liquidity of the received Series D Preferred Stock and warrants from Onconetix, Inc. are uncertain. Investors should hold to observe the monetization strategy for these equity instruments and the overall financial performance of Veru Inc. before making further investment decisions.

Keywords

Veru Inc., Onconetix Inc., debt settlement, promissory notes, Series D Preferred Stock, warrants, corporate finance, SEC filing, 8-K